GSWM
RXRX icon

Golden State Wealth Management’s Recursion Pharmaceuticals RXRX Stock Holding History

Golden State Wealth Management’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-385
Closed -$2.04K – 1651
2025
Q1 		$2.04K Hold
385
– – ﹤0.01% 1317
2024
Q4 		$2.6K Buy
+385
New +$2.59K ﹤0.01% 1223

Other funds holding RXRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
KA
Kinnevik AB Stockholm, Sweden $65.6M AUM 25.95% 1-Year Est. Return
MIC
Mubadala Investment Company Abu Dhabi, United Arab Emirates $20.5B AUM 19.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return

Golden State Wealth Management's RXRX Position: Q2 2025 in Review

Golden State Wealth Management sold out of Recursion Pharmaceuticals (RXRX) in Q2 2025, closing a stake of 385 shares — an estimated $2.04K sold.

Golden State Wealth Management first reported a position in RXRX in Q4 2024 and held it in 2 quarters. The position peaked at $2.6K in Q4 2024. 332 funds tracked by Wall St. Rank hold RXRX as of Q2 2025.

  • Golden State Wealth Management reported no remaining Recursion Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Golden State Wealth Management sold 385 Recursion Pharmaceuticals shares in Q2 2025, an estimated $2.04K.
  • Golden State Wealth Management first reported a position in Recursion Pharmaceuticals in Q4 2024 and held it in 2 quarters.
  • Golden State Wealth Management's Recursion Pharmaceuticals position peaked at $2.6K in Q4 2024.
  • 332 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2025.

Based on Golden State Wealth Management's 13F filing for Q2 2025, filed 6 Aug 2025.